Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy | 6 | 2023 | 231 | 2.390 |
Why?
|
| Radiotherapy | 3 | 2019 | 63 | 1.830 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 139 | 1.740 |
Why?
|
| Head and Neck Neoplasms | 5 | 2023 | 153 | 1.440 |
Why?
|
| Prostatic Neoplasms | 4 | 2017 | 319 | 1.210 |
Why?
|
| Prostate-Specific Antigen | 4 | 2017 | 66 | 1.080 |
Why?
|
| Lung Neoplasms | 3 | 2020 | 555 | 0.990 |
Why?
|
| Combined Modality Therapy | 7 | 2023 | 354 | 0.940 |
Why?
|
| Brachytherapy | 3 | 2013 | 40 | 0.820 |
Why?
|
| Neoplasms | 5 | 2019 | 1244 | 0.580 |
Why?
|
| Prostatectomy | 2 | 2017 | 46 | 0.570 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2012 | 34 | 0.570 |
Why?
|
| Adenocarcinoma | 2 | 2011 | 323 | 0.550 |
Why?
|
| Neoplasm Metastasis | 5 | 2019 | 196 | 0.490 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 454 | 0.470 |
Why?
|
| Kallikreins | 1 | 2013 | 9 | 0.450 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 21 | 0.450 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2014 | 234 | 0.430 |
Why?
|
| Induction Chemotherapy | 1 | 2011 | 33 | 0.380 |
Why?
|
| Radiation Injuries | 1 | 2010 | 56 | 0.330 |
Why?
|
| Antibodies, Monoclonal | 6 | 2020 | 856 | 0.290 |
Why?
|
| Antigens, Neoplasm | 5 | 2006 | 135 | 0.290 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2007 | 3 | 0.290 |
Why?
|
| Melanoma, Experimental | 1 | 2007 | 42 | 0.280 |
Why?
|
| Humans | 25 | 2023 | 59471 | 0.280 |
Why?
|
| Radiosurgery | 2 | 2019 | 61 | 0.270 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2007 | 87 | 0.270 |
Why?
|
| Antineoplastic Agents | 4 | 2017 | 645 | 0.260 |
Why?
|
| Endothelial Cells | 1 | 2007 | 176 | 0.260 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 215 | 0.250 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 441 | 0.250 |
Why?
|
| Dendritic Cells | 2 | 2007 | 508 | 0.240 |
Why?
|
| Pyrroles | 3 | 2015 | 50 | 0.240 |
Why?
|
| Indoles | 3 | 2015 | 98 | 0.240 |
Why?
|
| Tumor Microenvironment | 2 | 2019 | 143 | 0.230 |
Why?
|
| Immunotherapy, Active | 1 | 2003 | 4 | 0.230 |
Why?
|
| Epitopes | 3 | 2019 | 295 | 0.220 |
Why?
|
| Immunization, Passive | 1 | 2003 | 100 | 0.220 |
Why?
|
| Myeloid Cells | 2 | 2015 | 92 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2019 | 646 | 0.190 |
Why?
|
| Patient Selection | 1 | 2023 | 447 | 0.190 |
Why?
|
| Treatment Outcome | 5 | 2018 | 5174 | 0.190 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 1129 | 0.180 |
Why?
|
| Survival Analysis | 3 | 2012 | 553 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 220 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 41 | 0.170 |
Why?
|
| Middle Aged | 9 | 2017 | 16259 | 0.160 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 66 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 61 | 0.160 |
Why?
|
| Aged, 80 and over | 6 | 2017 | 5098 | 0.160 |
Why?
|
| Antigens | 1 | 2019 | 146 | 0.160 |
Why?
|
| Radium | 1 | 2017 | 2 | 0.150 |
Why?
|
| Male | 10 | 2017 | 27561 | 0.150 |
Why?
|
| Tissue Extracts | 1 | 2017 | 13 | 0.150 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2017 | 7 | 0.150 |
Why?
|
| Taxoids | 1 | 2017 | 26 | 0.150 |
Why?
|
| Organophosphorus Compounds | 1 | 2017 | 32 | 0.150 |
Why?
|
| Tumor Burden | 1 | 2017 | 62 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2017 | 73 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 279 | 0.140 |
Why?
|
| Treatment Failure | 2 | 2017 | 188 | 0.140 |
Why?
|
| Organometallic Compounds | 1 | 2017 | 64 | 0.140 |
Why?
|
| Aged | 7 | 2017 | 13342 | 0.140 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 79 | 0.140 |
Why?
|
| Neoplasm Grading | 2 | 2017 | 74 | 0.130 |
Why?
|
| Antibodies, Neoplasm | 2 | 2006 | 27 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2015 | 608 | 0.130 |
Why?
|
| Survival Rate | 3 | 2017 | 790 | 0.120 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2014 | 7 | 0.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2006 | 165 | 0.110 |
Why?
|
| New York City | 1 | 2013 | 75 | 0.110 |
Why?
|
| Melanoma | 3 | 2006 | 334 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 233 | 0.110 |
Why?
|
| Risk Factors | 3 | 2014 | 5010 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2014 | 6007 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 672 | 0.100 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2012 | 14 | 0.100 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2012 | 9 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2014 | 97 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 48 | 0.100 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 58 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 96 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 52 | 0.100 |
Why?
|
| Palladium | 1 | 2011 | 6 | 0.100 |
Why?
|
| Radioisotopes | 1 | 2011 | 24 | 0.100 |
Why?
|
| Molecular Mimicry | 3 | 2006 | 35 | 0.100 |
Why?
|
| Iodine Radioisotopes | 1 | 2011 | 51 | 0.100 |
Why?
|
| Binding Sites, Antibody | 3 | 2006 | 29 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 925 | 0.090 |
Why?
|
| Reference Values | 1 | 2011 | 319 | 0.090 |
Why?
|
| Risk | 1 | 2011 | 373 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2010 | 138 | 0.090 |
Why?
|
| Antibody Specificity | 2 | 2007 | 99 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2011 | 576 | 0.090 |
Why?
|
| Immune Tolerance | 1 | 2010 | 169 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2011 | 254 | 0.080 |
Why?
|
| Female | 7 | 2014 | 30895 | 0.080 |
Why?
|
| Adult | 4 | 2014 | 15771 | 0.080 |
Why?
|
| Histones | 1 | 2012 | 463 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 404 | 0.080 |
Why?
|
| Mice | 6 | 2007 | 10274 | 0.070 |
Why?
|
| Hybrid Cells | 1 | 2007 | 19 | 0.070 |
Why?
|
| Animals | 9 | 2012 | 19649 | 0.070 |
Why?
|
| HIV Infections | 1 | 2014 | 920 | 0.070 |
Why?
|
| Prevalence | 1 | 2010 | 1284 | 0.060 |
Why?
|
| HLA-A2 Antigen | 1 | 2006 | 65 | 0.060 |
Why?
|
| Immunotoxins | 1 | 2005 | 7 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2005 | 34 | 0.060 |
Why?
|
| CD4 Antigens | 1 | 2006 | 156 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2005 | 164 | 0.060 |
Why?
|
| Young Adult | 2 | 2012 | 4321 | 0.060 |
Why?
|
| Antibody Affinity | 1 | 2004 | 18 | 0.060 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2004 | 32 | 0.060 |
Why?
|
| Adolescent | 2 | 2012 | 5917 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2010 | 2443 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2005 | 352 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2012 | 1374 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 2327 | 0.050 |
Why?
|
| CD11b Antigen | 2 | 2015 | 21 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 1913 | 0.050 |
Why?
|
| Peptides | 1 | 2006 | 545 | 0.050 |
Why?
|
| Cell Survival | 2 | 2015 | 557 | 0.050 |
Why?
|
| United States | 2 | 2014 | 7516 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 3193 | 0.040 |
Why?
|
| Prognosis | 2 | 2012 | 1572 | 0.040 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2015 | 1 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 68 | 0.030 |
Why?
|
| Neck Dissection | 1 | 2014 | 19 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 237 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 77 | 0.030 |
Why?
|
| Immune System | 1 | 2015 | 129 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 102 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2005 | 879 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 638 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 303 | 0.030 |
Why?
|
| Monocytes | 1 | 2015 | 345 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2014 | 102 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 859 | 0.030 |
Why?
|
| Ribonucleotide Reductases | 1 | 2012 | 7 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2012 | 16 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 124 | 0.030 |
Why?
|
| Cetuximab | 1 | 2012 | 8 | 0.020 |
Why?
|
| Hydroxyurea | 1 | 2012 | 22 | 0.020 |
Why?
|
| Eye | 1 | 2012 | 54 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2012 | 54 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 192 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 942 | 0.020 |
Why?
|
| Alcoholism | 1 | 2014 | 307 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1046 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 233 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 316 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 733 | 0.020 |
Why?
|
| DNA Damage | 1 | 2012 | 280 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2012 | 379 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2010 | 32 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2012 | 376 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 483 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 829 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 702 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 200 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2012 | 480 | 0.020 |
Why?
|
| DNA | 1 | 2012 | 792 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 1038 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 3578 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2006 | 33 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2006 | 28 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2006 | 100 | 0.020 |
Why?
|
| Enterotoxins | 1 | 2006 | 21 | 0.020 |
Why?
|
| Laminin | 1 | 2006 | 74 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2006 | 106 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2006 | 137 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 2006 | 48 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2006 | 142 | 0.020 |
Why?
|
| Collagen | 1 | 2006 | 116 | 0.020 |
Why?
|
| Hemocyanins | 1 | 2005 | 23 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2006 | 82 | 0.020 |
Why?
|
| Inovirus | 1 | 2005 | 2 | 0.020 |
Why?
|
| Immunization | 1 | 2006 | 127 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2005 | 22 | 0.020 |
Why?
|
| Rabbits | 1 | 2006 | 330 | 0.020 |
Why?
|
| Peptide Library | 1 | 2005 | 35 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 2006 | 126 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2005 | 46 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2005 | 188 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2005 | 145 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 2068 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2006 | 363 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2006 | 343 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 193 | 0.010 |
Why?
|
| Gene Library | 1 | 2004 | 99 | 0.010 |
Why?
|
| Cell Movement | 1 | 2006 | 423 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 452 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2004 | 99 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 385 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 542 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2005 | 228 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 501 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 448 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 739 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 693 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 1223 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 1094 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2013 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1553 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 1552 | 0.010 |
Why?
|